Orris

Define Beta Blockers..?

Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Finding Sources
Reading File
Finding Sources
Reading File
Finding Sources
Reading File
Reading File
Reading File
I now have comprehensive information from multiple authoritative textbooks. Here is a complete definition and overview of beta blockers:

Beta Blockers (β-Adrenergic Blocking Agents)

Definition

Beta blockers are a class of drugs that competitively antagonize catecholamines (epinephrine, norepinephrine) at β-adrenergic receptors, thereby blocking the sympathetic nervous system's effects on the heart and other organs. They are structurally related to isoproterenol (a pure β-agonist) and have been among the most widely prescribed drug classes since the 1970s.

Mechanism of Action

Beta blockers block the catecholamine effects of:
  • Inotropy — increased myocardial contraction (β₁)
  • Chronotropy — increased heart rate (β₁)
  • Dromotropy — enhanced cardiac conduction (β₁)
β₂ effects that are blocked include: vascular smooth muscle relaxation, bronchodilation, glycogenolysis/gluconeogenesis in the liver, free fatty acid release from adipose tissue, and uterine smooth muscle relaxation.
In heart failure, they interfere with the harmful effects of sustained sympathetic activation by competitively antagonizing α₁, β₁, and β₂ adrenergic receptors, with most deleterious effects mediated via the β₁ receptor.
  • Braunwald's Heart Disease, p. 154
  • ROSEN's Emergency Medicine, p. 1476

Classification

Beta blockers are classified based on several key properties:
PropertyExamplesNotes
Non-selective (β₁ + β₂)Propranolol, Nadolol, Timolol, SotalolPrototype: Propranolol
Cardioselective (β₁ only)Metoprolol, Atenolol, Bisoprolol, Esmolol, BetaxololPreferred in most patients
α + β blockadeCarvedilol, LabetalolAlso vasodilatory
Intrinsic Sympathomimetic Activity (ISA)Pindolol, Penbutolol, AcebutololPartial agonists — avoid in angina/post-MI
Membrane-stabilizing activityPropranololFast Na⁺ channel blocking; most toxic in overdose
  • Katzung's Basic and Clinical Pharmacology, 16th Ed.
  • Lippincott Illustrated Reviews: Pharmacology

Clinical Indications

  • Angina pectoris — first-line for stable angina (reduce heart rate and contractility → ↓ myocardial O₂ demand)
  • Hypertension — decrease cardiac output and plasma renin activity
  • Heart failure with reduced EF (HFrEF) — three agents proven to reduce mortality: bisoprolol, sustained-release metoprolol succinate, carvedilol
  • Post-myocardial infarction — reduce total and sudden cardiac death
  • Supraventricular dysrhythmias
  • Thyrotoxicosis
  • Migraine prophylaxis
  • Glaucoma (topical: timolol, betaxolol, carteolol)
  • Acute coronary syndrome
  • ROSEN's Emergency Medicine, p. 1471
  • Lippincott Illustrated Reviews: Pharmacology, p. 418

Commonly Used Agents

DrugBrand NameNotable Feature
PropranololInderalNon-selective; prototype; most toxic in OD
MetoprololLopressor, ToprolCardioselective (β₁)
AtenololTenorminCardioselective
BisoprololZebetaCardioselective; used in HF
CarvedilolCoregα₁ + β₁ + β₂ blocker; used in HF
LabetalolTrandateα + β; used in hypertensive urgency
EsmololBreviblocUltra short-acting IV; cardioselective
SotalolBetapaceAlso a class III antiarrhythmic
TimololTimopticOphthalmic (glaucoma)
NebivololBystolicVasodilation via NO release
PindololViskenHas ISA
  • Katzung's Basic and Clinical Pharmacology, 16th Ed., p. 265

Adverse Effects & Precautions

  • Bradycardia and hypotension — most common
  • Bronchoconstriction — from β₂ blockade; non-selective agents contraindicated in asthma
  • Masking of hypoglycemia — blocks epinephrine-mediated symptoms (tremor, palpitations, anxiety); diaphoresis (cholinergic) is the only remaining clue
  • Worsening of HF — early transient deterioration due to negative inotropy; avoided by slow up-titration
  • Fatigue, cold extremities, depression
  • Rebound angina/MI/hypertension on abrupt withdrawal — must be tapered over 2–3 weeks
  • Lippincott Illustrated Reviews: Pharmacology, p. 449
  • Braunwald's Heart Disease, p. 154

Contraindications

  • Significant bradycardia or high-degree AV block
  • Severe reactive airway disease (asthma) — with non-selective agents
  • Vasospastic (Prinzmetal) angina — β-blockers are ineffective and may worsen coronary spasm
  • ISA agents (e.g., pindolol) — avoid in angina and post-MI patients

Overdose / Toxicity

In overdose, all selectivity is lost. The most toxic agent is propranolol (lipophilic → CNS entry; sodium channel blocking → wide QRS, seizures). Key features: bradycardia, hypotension, AV block. Treatment includes atropine, IV fluids, high-dose insulin/glucose (HDI) infusion, and glucagon (raises intracellular cAMP independent of β-receptors; 5–10 mg IV).
  • Katzung's Basic and Clinical Pharmacology, p. 1624
  • ROSEN's Emergency Medicine, p. 1459
In summary: Beta blockers are cornerstone cardiovascular drugs acting by competitive blockade of β-adrenergic receptors, reducing heart rate, contractility, and blood pressure. Their spectrum ranges from non-selective (propranolol) to cardioselective (metoprolol, bisoprolol) to mixed α/β blockers (carvedilol, labetalol), each with distinct clinical niches and safety profiles.

Exam Points Only

Beta Blockers — Exam Points

Definition

  • Competitive antagonists at β-adrenergic receptors
  • Block effects of catecholamines (epinephrine, norepinephrine)

Receptor Selectivity

  • β₁ → Heart (↓HR, ↓contractility, ↓conduction)
  • β₂ → Lungs (bronchodilation), liver (glycogenolysis), vessels (vasodilation)
  • α₁ → Vasoconstriction (blocked by carvedilol/labetalol only)

Classification (HIGH YIELD)

TypeDrugs
Non-selective (β₁+β₂)Propranolol, Nadolol, Timolol, Sotalol
Cardioselective (β₁ only)Metoprolol, Atenolol, Bisoprolol, Esmolol
α+β blockerCarvedilol, Labetalol
Has ISAPindolol, Acebutolol
Memory: "MABE" = Metoprolol, Atenolol, Bisoprolol, Esmolol → cardioselective

Indications

  • Angina (first-line, except vasospastic/Prinzmetal)
  • Hypertension
  • HFrEF — only 3 proven: Bisoprolol, Metoprolol succinate, Carvedilol
  • Post-MI (↓sudden death)
  • SVT / Rate control in AF
  • Thyrotoxicosis
  • Migraine prophylaxis
  • Glaucoma (topical: Timolol, Betaxolol)

Contraindications

  • Asthma / severe COPD (non-selective agents)
  • Bradycardia / High-degree AV block
  • Prinzmetal angina (worsen coronary spasm)
  • ISA agents contraindicated post-MI and in angina

Adverse Effects

  • Bradycardia, hypotension
  • Bronchoconstriction (β₂ block)
  • Masks hypoglycemia symptoms — except diaphoresis (cholinergic, still present)
  • Fatigue, cold extremities
  • Abrupt withdrawal → rebound angina, MI, hypertension → taper over 2–3 weeks

Key High-Yield Facts

  • Prototype = Propranolol (non-selective)
  • Most toxic in overdose = Propranolol (lipophilic → CNS; Na⁺ channel block → seizures, wide QRS)
  • Antidote for overdose = Glucagon (5–10 mg IV)
  • All selectivity lost in overdose
  • Cardioselective agents still safer in OD (lower mortality than propranolol)
  • Esmolol = ultra-short acting IV (t½ ~9 min)
  • Nebivolol = vasodilation via NO release
  • Sotalol = also Class III antiarrhythmic
  • Do NOT use ISA agents (pindolol) in angina or post-MI
  • Bisoprolol and metoprolol succinate → block β₁ only; Carvedilol → blocks α₁, β₁, β₂

Pharmacokinetics Pearl

  • Lipophilic (propranolol) → crosses BBB → CNS side effects
  • Hydrophilic (atenolol) → renally excreted → less CNS penetration
  • Hepatic first-pass for propranolol (oral bioavailability ~30%)
This is a shared conversation. Sign in to Orris to start your own chat.